What is Karyopharm Therapeutics Inc. (KPTI)?

Karyopharm Therapeutics Inc. (KPTI) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of KPTI?

The current price of KPTI is $0.83. Prices are updated in real time on Stocks360.

What is KPTI's price-to-earnings (PE) ratio?

KPTI's trailing twelve-month PE ratio is -0.04, based on current price and earnings per share data available on Stocks360.

What is KPTI's market capitalization?

KPTI's market capitalization is $18,873,243.00, placing it in the small-cap tier.

Karyopharm Therapeutics Inc. (KPTI)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.83

Market Cap

$18.87M

PE (TTM)

-0.04

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.04

Day Range

$0.46 – $0.91

52-wk Range

$0.31 – $10.99

Avg Volume

N/A

Volume

53.80M

Karyopharm Therapeutics Inc. (KPTI) is a publicly traded company in the Healthcare sector. Latest price: $0.83. Market cap $18.87M. Trailing PE -0.04. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $6.08 2026-10-28 · $0.83 (-86.31%)

Earnings

Most Recent

Aug 13, 2026

EPS $-2.32 vs est. $-1.37

Missed by $0.95

Next Earnings

Nov 2, 2026

EPS estimate $-0.95

Proprietary Signals

Signal snapshot temporarily unavailable.

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.04×
P/S (TTM)	0.13×
P/B	-0.07×
PEG	0.00×
P/FCF (TTM)	-0.29×
EV / EBITDA	-1.02×
EV / Sales	1.23×
Earnings Yield	-933.33%
Free Cash Flow Yield	-346.24%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$179.78M
Revenue (TTM)	$146.62M
Net Income (TTM)	-$176.15M
Free Cash Flow (TTM)	-$16.03M
Net Debt	$160.91M
Working Capital	-$27.86M
Gross Margin	95.88%
Operating Margin	-56.17%
Net Margin	-153.28%
Return on Equity	77.63%
Return on Invested Capital	376.87%